CTA
CRSP icon

Colonial Trust Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Colonial Trust Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.94K Hold
209
– – ﹤0.01% 533
2025
Q4 		$11K Sell
209
-41
-16% -$2.46K ﹤0.01% 501
2025
Q3 		$16.2K Sell
250
-200
-44% -$11.5K ﹤0.01% 447
2025
Q2 		$21.9K Hold
450
– – ﹤0.01% 435
2025
Q1 		$15.3K Buy
450
+60
+15% +$2.54K ﹤0.01% 458
2024
Q4 		$15.3K Hold
390
– – ﹤0.01% 437
2024
Q3 		$18.3K Buy
390
+41
+12% +$2.08K ﹤0.01% 460
2024
Q2 		$18.8K Buy
349
+50
+17% +$2.89K ﹤0.01% 434
2024
Q1 		$20.4K Hold
299
– – ﹤0.01% 475
2023
Q4 		$18.7K Sell
299
-51
-15% -$2.82K ﹤0.01% 422
2023
Q3 		$15.9K Buy
350
+50
+17% +$2.58K ﹤0.01% 460
2023
Q2 		$16.8K Buy
300
+100
+50% +$5.67K ﹤0.01% 458
2023
Q1 		$9.05K Sell
200
-199
-50% -$9.66K ﹤0.01% 530
2022
Q4 		$16.2K Buy
+399
New +$21.2K ﹤0.01% 449

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Colonial Trust Advisors's CRSP Position: Q1 2026 in Review

Colonial Trust Advisors held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 209 shares worth $9.94K. The position accounts for ﹤0.01% of the portfolio, ranked #533.

Colonial Trust Advisors first reported a position in CRSP in Q4 2022 and has held it in 14 quarters since. The position peaked at $21.9K in Q2 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Colonial Trust Advisors held 209 shares of CRISPR Therapeutics worth $9.94K as of Q1 2026.
  • Colonial Trust Advisors left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q1 2026, its #533 holding.
  • Colonial Trust Advisors first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Colonial Trust Advisors's CRISPR Therapeutics position peaked at $21.9K in Q2 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Colonial Trust Advisors's 13F filing for Q1 2026, filed 12 May 2026.